-

09:22:10 PM

VXRT Stock News

VXRT - Vaxart Inc

07/01/22 9:00 AM

Nasdaq : VXRT

Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET

Vaxart, Inc. (Nasdaq: VXRT) today urges its stockholders

RHEA-AI

positive

06/30/22 8:00 AM

Nasdaq : VXRT

Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model

Vaxart, Inc. (Nasdaq: VXRT) today announced an agreement with hVIVO

RHEA-AI

neutral

06/16/22 4:05 PM

Nasdaq : VXRT

conferences

Vaxart to Host Investor Q&A Webcast

Vaxart, Inc. (Nasdaq: VXRT) today announced that it will host a question-and-answer webcast with

RHEA-AI

neutral

06/08/22 9:05 AM

Nasdaq : VXRT

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart”)

RHEA-AI

neutral

06/03/22 8:00 AM

Nasdaq : VXRT

clinical trialcovid-19

New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron

Vaxart, Inc. (NASDAQ: VXRT) today reported positive preliminary preclinical data demonstrating that two COVID-19 vaccine candidates

RHEA-AI

negative

06/02/22 8:30 AM

Nasdaq : VXRT

clinical trial

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

RHEA-AI

neutral

06/02/22 8:00 AM

Nasdaq : VXRT

conferences

Vaxart to Participate at the Jefferies Global Healthcare Conference

Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a fireside

RHEA-AI

neutral

05/19/22 8:30 AM

Nasdaq : VXRT

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

Science Translational Medicine has published the results of a Duke

RHEA-AI

neutral

05/09/22 5:46 PM

Nasdaq : VXRT

earnings

Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results

Vaxart, Inc. (NASDAQ: VXRT) issued its business update

RHEA-AI

neutral

04/14/22 8:30 AM

Nasdaq : VXRT

conferences

Vaxart to Present at World Vaccine Congress Washington 2022 on April 20

Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 in Washington, D.C. on Wednesday, April 20, 2022 at 3:55 p.m. ET. The

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

VXRT Data

Websitevaxart.com
Security nameVaxart Inc
Issue typecs
Sic code2836
Employees28
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing

About Vaxart Inc

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.